Efficacy of Propranolol Treatment to Prevent Melanoma Progression

• Status: Suspended
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its metastatic stage. Three recent retrospective studies compared groups of patients diagnosed with primary melanoma and treated with betablockers for another indication to patients who never received betablockers. In these three studies, the outcome of the disease is significantly better for people under betablocker treatment with a decreased rate of recurrence and a better 5 years survival rate. Here we want to investigate the efficacy and the tolerability of an adjuvant treatment with propranolol for patients suffering from a primary melanoma with a high risk of recurrence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Geneva
• Treatments: Propranolol

Criteria

Inclusion Criteria:

• patient over 18 y.o

• Breslow index > 1mm or any Breslow index with ulcerated primary lesion

• Melanoma stage AJCC Ib, IIa, IIb, IIc, IIIa, IIIb or IIIc

• Able to undergo outpatient treatment

Exclusion Criteria:

• No contra indication for betablockers as defined by the compendium

• No clinical evidence of coagulopathy

• No unstable angina pectoris

• No AV-block II or III without pacemaker

• No severe congestive heart failure

• No untreated phaeochromocytoma

• No severe bradycardia

• No severe hypotension

• No severe impairment of peripheral arterial circulation

• No uncontrolled cardiac arrhythmia

• No severe asthma or COPD

• No uncontrolled diabetes mellitus

• No Angioneurotic edema

• No severe Aortic valve stenosis

• No severe hypertrophic cardiomyopathy

• No severe renal dysfunction

• No patients on beta blockers by inclusion

• No known adverse reaction to betablockers

• No pregnant or lactating patients can be included

• No melanoma stage AJCC IV by inclusion

• No patients requiring a specific oncological treatment